Overview

The Gene Technology Act 2000, enacted by the Parliament of Australia, establishes a regulatory framework to manage the potential risks posed by gene technology to human health and the environment. The Act was introduced to address the need for a systematic approach to regulating the development, use, and release of genetically modified organisms (GMOs) within Australia, ensuring that any potential risks are identified and appropriately managed. The Office of the Gene Technology Regulator (OGTR), as the body responsible for administering the Act, aims to facilitate the safe and responsible use of gene technology while promoting innovation and public confidence in its applications. In this context, the OGTR is currently assessing an application from Syngenta Australia Pty Ltd for the commercial cultivation of genetically modified cotton, with a focus on ensuring that the proposed release poses negligible risk to human health and the environment. Public consultation is invited to finalise the Risk Assessment and Risk Management Plan (RARMP) that will inform the decision on whether to grant the licence for commercial release.

Scope and Application

The legislation in question, C2017G01230, pertains to the assessment of a licence application by Syngenta Australia Pty Ltd for the commercial cultivation of genetically modified (GM) cotton, specifically the GM cotton line COT102. This application falls under the purview of Australia’s gene technology regulatory system, which is overseen by the Gene Technology Regulator. The Act applies to Syngenta as the applicant and potentially to any party affected by the commercial release of COT102. Its geographic reach encompasses all cotton-growing areas of Australia, with the GM cotton and its products intended for general commerce, including use in human food and animal feed. The Act does not specify exclusions or exemptions but requires a Risk Assessment and Risk Management Plan (RARMP) to evaluate potential risks to human health and safety and the environment. The Regulator is open to public submissions to finalise the RARMP and determine the licence conditions, ensuring ongoing oversight of the release. The consultation period for submissions closes on 10 January 2018, providing an opportunity for stakeholders to contribute to the regulatory decision-making process.

Key Provisions

The primary provisions of the legislation (C2017G01230) involve the assessment and potential approval of the commercial release of genetically modified cotton by Syngenta Australia Pty Ltd. Section 1 outlines the purpose of the gene technology regulatory system, which is to safeguard human health and environmental safety by managing the risks associated with gene technology. Section 3 details the specific application (DIR 157) for commercial cultivation of genetically modified cotton (COT102) by Syngenta. This application includes the introduction of a gene conferring insect resistance and a selectable marker gene for antibiotic resistance. Section 4 explains that Syngenta seeks approval to grow COT102 in all cotton-growing regions of Australia, with its products entering general commerce, including human food and animal feed. The obligations and requirements imposed by the Act on Syngenta and the Gene Technology Regulator include the preparation of a comprehensive Risk Assessment and Risk Management Plan (RARMP), as mentioned in Section 2. This plan must conclude that the proposed release poses negligible risk to human health and safety or the environment. Draft licence conditions are proposed in Section 5 to ensure ongoing oversight of the release. Syngenta must also facilitate public consultation by inviting written submissions to finalise the RARMP, which will inform the decision on whether to issue the licence. The Office of the Gene Technology Regulator (OGTR) is responsible for overseeing this process, receiving submissions, and making the consultation RARMP and related documents accessible to the public. Section 6 of the Act outlines the potential consequences for non-compliance or breaches of the Act’s provisions. While the specific penalties for breaches are not detailed in the text provided, it is typical for breaches of gene technology regulations to incur civil or criminal penalties. Civil penalties may include fines, while criminal penalties could involve imprisonment, depending on the severity of the breach. The Act also stipulates the importance of obtaining and adhering to the proposed licence conditions to ensure the safe commercial release of genetically modified cotton. Failure to comply with these conditions may result in the revocation of the licence or other legal actions.